Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05188027
Other study ID # Pro00107673
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date November 16, 2021
Est. completion date December 30, 2025

Study information

Verified date January 2024
Source University of Alberta
Contact Jane E Yardley, PhD
Phone 780-679-1688
Email jane.yardley@ualberta.ca
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Participants will be asked to wear a continuous glucose monitor for at least three days on three separate occasions. One testing session will be a no-exercise resting control session (90 minutes). One will be a moderate aerobic exercise session (30 minutes of exercise, 60 minutes of recovery), and the third will be a moderate weight-lifting session (~30 minutes of exercise, 60 minutes of recovery).The investigators will measure changes in blood glucose during exercise by drawing blood during and after exercise. Post-exercise glucose trends will be examined using continuous glucose monitoring.


Description:

Pre-test measures: Interested participants will be invited to either the Exercise Physiology laboratory the Augustana campus of the University of Alberta, or the Physical Activity and Diabetes Laboratory on the main campus of the University of Alberta. They will be asked questions related to menopause, PA levels, and medication. Blood pressure and heart rate will also be measured. Where participants are eligible, anthropometric characteristics will be measured using standard protocols. A blood sample will be drawn for assessment of HbA1c. Those who meet all eligibility criteria and complete informed consent forms will be asked to complete the initial exercise tests. Participants will perform a maximal aerobic capacity test with ECG monitoring, under the supervision of a certified exercise physiologist. Indirect calorimetry will be used to assess oxygen consumption and carbon dioxide production and will be used to extrapolate the participant's aerobic capacity. Participants will undergo a strength test for each of the ten exercises involved in the study, in order to estimate the their 1 repetition maximum. Participants will also be asked to undergo a dual energy x-ray absorptiometry (DXA) scan for body composition in the Clinical Research Unit at the Alberta Diabetes Institute. While this procedure generally requires proof of a negative pregnancy test, participants will be provided with a waiver in order to decline this test (in light of their menopausal status). Testing sessions: Participants will be asked to arrive at the lab at around 4:00 pm for all three sessions, which will be randomly assigned. During the sessions, participants will be asked to perform one of the three activities: 1) seated rest 2) aerobic exercise (walking on a treadmill at 50% of the participant's pre-determined VO2max) or 3) resistance exercise consisting of 1 set of 10 repetitions of 10 different exercises with 90 seconds rest between sets. Blood samples will be drawn at baseline, after 10, 20 and 30 minutes of exercise, along with 30- and 60-minutes post-exercise via an IV catheter. Indirect calorimetry will be used to ensure that the participant is exercising at the appropriate intensity. Participants will be asked to match their daily food and insulin intake as closely as possible from one testing session to the next for the day before, day of and day after the testing session. The investigators will provide them with log sheets to assist in this task. They will also be asked to avoid strenuous exercise and alcohol intake. A CGM sensor will be subcutaneously inserted by one of the investigators (trained by a group from the CGM manufacturer) into the anterior abdominal area of the participant, or on the back of the arm of the participant, approximately 2 days prior to the first testing session. The Dexcom G6 CGM receiver will store glucose data every 5 minutes for up to 10 days. The participant will be instructed on how to remove their sensor at least 24 hours after the exercise session, and will be asked to return the receiver to enable the upload of their data to Dexcom Clarity by the study team. Interviews: During the third and final testing session, study participants will be invited to answer questions about their study participation experience, exercise preferences, barriers to exercise, and other information they feel may improve their exercise experience. These interviews will be audio recorded and transcribed.


Recruitment information / eligibility

Status Recruiting
Enrollment 20
Est. completion date December 30, 2025
Est. primary completion date December 30, 2025
Accepts healthy volunteers No
Gender Female
Age group 45 Years to 75 Years
Eligibility Inclusion Criteria: - type 1 diabetes, diagnosed for at least one year - post-menopause (at least one year since last menstrual period), or have had a hysterectomy and bilateral salpingo oophorectomy - able to perform aerobic and resistance exercise - able to visit the lab in Edmonton, Alberta (University of Alberta) Exclusion Criteria: - HbA1c > 9.9 % - frequent and unpredictable hypoglycemia - change in insulin management strategy within the last 2 months - blood pressure > 140 / 95 - severe peripheral neuropathy - history of cardiovascular disease - musculoskeletal injuries interfering with exercise performance - use of medications (other than insulin) that affect glucose metabolism - BMI > 30 kg/m2 - smoking - moderate to high alcohol intake (> 2 drinks/day)

Study Design


Intervention

Other:
Aerobic Exercise
Walking at 60% of maximal aerobic capacity on a treadmill
Resistance Exercise
Performing one set of 10 repetitions of 10 different weight-lifting exercises
No exercise
Participants will rest in a supine position for 30 minutes.

Locations

Country Name City State
Canada Alberta Diabetes Institute Edmonton Alberta
Canada Institut de recherches cliniques de Montréal Montreal Quebec

Sponsors (2)

Lead Sponsor Collaborator
University of Alberta Women and Children's Health Research Institute, Canada

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Blood glucose Change in blood glucose From 0 minutes to 45 minutes (beginning to the end of exercise/control) and then for 60 minutes after exercise
Secondary mean continuous glucose monitoring (CGM) glucose mean of all measurements over the selected time frames 6 hours, 12 hours, nocturnal (midnight to 6am) and 24 hours post-exercise
Secondary coefficient of variation (CV) of CGM glucose CV of CGM glucose over the selected time frames 6 hours, 12 hours, nocturnal (midnight to 6am) and 24 hours post-exercise
Secondary standard deviation (SD) SD of CGM glucose over the selected time frames 6 hours, 12 hours, nocturnal (midnight to 6am) and 24 hours post-exercise
Secondary frequency of hypoglycemia number of times that CGM glucose is equal to or less than 3.9 mmol/L 6 hours, 12 hours, nocturnal (midnight to 6am) and 24 hours post-exercise
Secondary frequency of hyperglycemia number of times that CGM glucose is equal to or greater than 10.0 mmol/L 6 hours, 12 hours, nocturnal (midnight to 6am) and 24 hours post-exercise
Secondary percent time spent in hyperglycemia percentage of time spent with CGM glucose equal to or greater than 10.0 mmol/L 6 hours, 12 hours, nocturnal (midnight to 6am) and 24 hours post-exercise
Secondary percent time spent in hypoglycemia percentage of time spent with CGM glucose equal to or lower than 3.9 mmol/L 6 hours, 12 hours, nocturnal (midnight to 6am) and 24 hours post-exercise
Secondary percent time spent in range percent of time spent with CGM glucose between 4.0 and 9.9 mmol/L 6 hours, 12 hours, nocturnal (midnight to 6am) and 24 hours post-exercise
Secondary carbohydrate supplementation grams of carbohydrate provided during exercise to prevent hypoglycemia from 0 minutes to 45 minutes (during exercise)
See also
  Status Clinical Trial Phase
Recruiting NCT05653518 - Artificial Pancreas Technology to Reduce Glycemic Variability and Improve Cardiovascular Health in Type 1 Diabetes N/A
Enrolling by invitation NCT05515939 - Evaluating the InPen in Pediatric Type 1 Diabetes
Completed NCT05109520 - Evaluation of Glycemic Control and Quality of Life in Adults With Type 1 Diabetes During Continuous Glucose Monitoring When Switching to Insulin Glargine 300 U/mL
Recruiting NCT04016987 - Automated Structured Education Based on an App and AI in Chinese Patients With Type 1 Diabetes N/A
Active, not recruiting NCT04190368 - Team Clinic: Virtual Expansion of an Innovative Multi-Disciplinary Care Model for Adolescents and Young Adults With Type 1 Diabetes N/A
Recruiting NCT05413005 - Efficacy of Extracorporeal Photopheresis (ECP) in the Treatment of Type 1 Diabetes Mellitus Early Phase 1
Active, not recruiting NCT04668612 - Dual-wave Boluses in Children With Type 1 Diabetes Insulin Boluses in Children With Type 1 Diabetes N/A
Completed NCT02837094 - Enhanced Epidermal Antigen Specific Immunotherapy Trial -1 Phase 1
Recruiting NCT05414409 - The Gut Microbiome in Type 1 Diabetes and Mechanism of Metformin Action Phase 2
Recruiting NCT05670366 - The Integration of Physical Activity Into the Clinical Decision Process of People With Type 1 Diabetes N/A
Active, not recruiting NCT05418699 - Real-life Data From Diabetic Patients on Closed-loop Pumps
Completed NCT04084171 - Safety of Artificial Pancreas Therapy in Preschoolers, Age 2-6 N/A
Recruiting NCT06144554 - Post Market Registry for the Omnipod 5 System in Children and Adults With Type 1 Diabetes
Recruiting NCT05153070 - Ciclosporin Followed by Low-dose IL-2 in Patients With Recently Diagnosed Type 1 Diabetes Phase 2
Recruiting NCT05379686 - Low-Dose Glucagon and Advanced Hybrid Closed-Loop System for Prevention of Exercise-Induced Hypoglycaemia in People With Type 1 Diabetes N/A
Completed NCT05281614 - Immune Effects of Vedolizumab With or Without Anti-TNF Pre-treatment in T1D Early Phase 1
Withdrawn NCT04259775 - Guided User-initiated Insulin Dose Enhancements (GUIDE) to Improve Outcomes for Youth With Type 1 Diabetes N/A
Active, not recruiting NCT01600924 - Study on the Assessment of Determinants of Muscle and Bone Strength Abnormalities in Diabetes
Completed NCT02914886 - Beneficial Effect of Insulin Glulisine by Lipoatrophy and Type 1 Diabetes (LAS) Phase 4
Completed NCT02855307 - Closed-loop Control of Glucose Levels (Artificial Pancreas) During Postprandial Exercise in Adults With Type 1 Diabetes Phase 2